Schlagwort: HBM Partners
The Biotech IP Flip: Scaling Up Instead of Selling
Many European biotech companies still view the U.S. market primarily as a future exit channel. Yet it can be leveraged much earlier - not...
Hookipa Biotech erhält 50 Mio. EUR aus überzeichneter Serie C-Finanzierung
Das Wiener Biotech-Unternehmen Hookipa Biotech, Spezialist für die Entwicklung von aktiven Immuntherapien gegen Krebs und Infektionskrankheiten, hat eine Serie C-Finanzierungsrunde abgeschlossen und dabei rund...
2015 was a record year for biopharma
2015 was a record year for biopharma M&A with a worldwide transaction volume of 430 Bio. USD, including asset deals and announced transactions. The deal volume of completed US transactions almost reached 200 Bio. USD, up from 90 Bio. USD in 2014